CA2658016A1 - Use of glucocorticoid receptor antagonists for treatment of infectious conditions - Google Patents
Use of glucocorticoid receptor antagonists for treatment of infectious conditions Download PDFInfo
- Publication number
- CA2658016A1 CA2658016A1 CA002658016A CA2658016A CA2658016A1 CA 2658016 A1 CA2658016 A1 CA 2658016A1 CA 002658016 A CA002658016 A CA 002658016A CA 2658016 A CA2658016 A CA 2658016A CA 2658016 A1 CA2658016 A1 CA 2658016A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- glucocorticoid receptor
- receptor antagonist
- mammalian subject
- dheas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 30
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 title claims abstract description 23
- 230000002458 infectious effect Effects 0.000 title claims abstract description 13
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 32
- 230000000638 stimulation Effects 0.000 claims abstract description 23
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 claims abstract description 22
- 210000000440 neutrophil Anatomy 0.000 claims abstract description 21
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 claims abstract description 19
- 230000032683 aging Effects 0.000 claims abstract description 18
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 14
- 210000002966 serum Anatomy 0.000 claims abstract description 14
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 claims abstract description 12
- 229960003248 mifepristone Drugs 0.000 claims abstract description 6
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 claims abstract 4
- 230000035882 stress Effects 0.000 claims description 17
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 206010020100 Hip fracture Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 abstract description 5
- 239000005557 antagonist Substances 0.000 description 22
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 21
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 21
- 230000000694 effects Effects 0.000 description 11
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- DFELGYQKEOCHOA-RBXNTRDFSA-N (11r,13s,17s)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C4CCC(=O)C=C4CCC3C3CC[C@@]([C@]3(C2)C)(O)C#CC)=C1 DFELGYQKEOCHOA-RBXNTRDFSA-N 0.000 description 8
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 206010000210 abortion Diseases 0.000 description 3
- 231100000176 abortion Toxicity 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001838 anti-progestagenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229960002847 prasterone Drugs 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DFELGYQKEOCHOA-ZRLOAUAMSA-N (8s,11r,13s,14s,17r)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@]([C@]3(C2)C)(O)C#CC)=C1 DFELGYQKEOCHOA-ZRLOAUAMSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000340987 Ptychopetalum olacoides Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 229920002472 Starch Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007380 inflammaging Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06118587.2 | 2006-08-08 | ||
| EP06118587 | 2006-08-08 | ||
| PCT/EP2007/058134 WO2008017658A2 (en) | 2006-08-08 | 2007-08-06 | Use of glucocorticoid receptor antagonists for treatment of infectious conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2658016A1 true CA2658016A1 (en) | 2008-02-14 |
Family
ID=37600754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002658016A Abandoned CA2658016A1 (en) | 2006-08-08 | 2007-08-06 | Use of glucocorticoid receptor antagonists for treatment of infectious conditions |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100075936A1 (es) |
| EP (2) | EP2051705A2 (es) |
| JP (1) | JP2010500323A (es) |
| KR (1) | KR20090039775A (es) |
| CN (1) | CN101500547A (es) |
| AR (1) | AR062229A1 (es) |
| AU (1) | AU2007283604A1 (es) |
| CA (1) | CA2658016A1 (es) |
| IL (1) | IL196392A0 (es) |
| MX (1) | MX2009000950A (es) |
| TW (1) | TW200820977A (es) |
| WO (1) | WO2008017658A2 (es) |
| ZA (1) | ZA200900242B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010052445A1 (en) | 2008-11-07 | 2010-05-14 | University Of Sheffield | Medicament and method of diagnosis |
| WO2012135274A1 (en) | 2011-03-31 | 2012-10-04 | Pop Test Cortisol Llc | Prevention of infection |
| WO2012145258A1 (en) * | 2011-04-18 | 2012-10-26 | Pop Test Cortisol Llc | Hair loss treatment |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
| EP3400233A4 (en) * | 2015-08-03 | 2020-02-26 | Pop Test Oncology LLC | PHARMACEUTICAL COMPOSITIONS AND METHODS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| ES2092958B1 (es) * | 1995-01-10 | 1997-08-01 | Miret Lab | Procedimiento para la sintesis de tensioactivos cationicos derivados de la condensacion de acidos grasos con aminoacidos de caracter basico esterificados y su aplicacion como agentes antimicrobianos. |
| IL118974A (en) | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| JP2000511404A (ja) * | 1996-04-09 | 2000-09-05 | ビー・テイー・ジー・インターナシヨナル・リミテツド | 神経精神、免疫又は内分泌障害を治療するための７α置換ステロイドの使用 |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| US6329534B1 (en) | 1999-09-01 | 2001-12-11 | Abbott Laboratories | Glucocorticoid receptor antagonists for treatment of diabetes |
| CA2455981C (en) * | 2001-08-09 | 2012-10-09 | Joan Baptista Urgell Beltran | Use of cationic surfactants in cosmetic preparations |
| MXPA04003855A (es) * | 2001-10-25 | 2004-07-08 | Miret Lab | Uso de consevadores cationicos en productos alimenticios. |
| AU2002358540A1 (en) * | 2001-11-30 | 2003-06-10 | Solvay Pharmaceuticals Gmbh | Treatment of th2 dominated immunological disease states with progesterone receptor antagonists |
| WO2005070893A2 (en) | 2004-01-09 | 2005-08-04 | Corcept Therapeutics, Inc. | Azadecalin glucocorticoid receptor modulators |
| JP4797326B2 (ja) * | 2004-01-27 | 2011-10-19 | 大正製薬株式会社 | 生薬含有組成物 |
-
2007
- 2007-07-19 TW TW096126375A patent/TW200820977A/zh unknown
- 2007-08-06 EP EP07788248A patent/EP2051705A2/en not_active Withdrawn
- 2007-08-06 US US12/375,744 patent/US20100075936A1/en not_active Abandoned
- 2007-08-06 AU AU2007283604A patent/AU2007283604A1/en not_active Abandoned
- 2007-08-06 EP EP10159050A patent/EP2204171A1/en not_active Withdrawn
- 2007-08-06 JP JP2009523270A patent/JP2010500323A/ja active Pending
- 2007-08-06 KR KR1020097002988A patent/KR20090039775A/ko not_active Application Discontinuation
- 2007-08-06 WO PCT/EP2007/058134 patent/WO2008017658A2/en active Application Filing
- 2007-08-06 CN CNA2007800292934A patent/CN101500547A/zh active Pending
- 2007-08-06 MX MX2009000950A patent/MX2009000950A/es not_active Application Discontinuation
- 2007-08-06 CA CA002658016A patent/CA2658016A1/en not_active Abandoned
- 2007-08-07 AR ARP070103470A patent/AR062229A1/es unknown
-
2009
- 2009-01-08 IL IL196392A patent/IL196392A0/en unknown
- 2009-01-12 ZA ZA2009/00242A patent/ZA200900242B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2204171A1 (en) | 2010-07-07 |
| TW200820977A (en) | 2008-05-16 |
| KR20090039775A (ko) | 2009-04-22 |
| CN101500547A (zh) | 2009-08-05 |
| IL196392A0 (en) | 2009-09-22 |
| AU2007283604A1 (en) | 2008-02-14 |
| US20100075936A1 (en) | 2010-03-25 |
| JP2010500323A (ja) | 2010-01-07 |
| AR062229A1 (es) | 2008-10-22 |
| EP2051705A2 (en) | 2009-04-29 |
| MX2009000950A (es) | 2009-02-04 |
| ZA200900242B (en) | 2011-06-29 |
| WO2008017658A3 (en) | 2008-04-10 |
| WO2008017658A2 (en) | 2008-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ling et al. | Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium | |
| Notelovitz | Estrogen replacement therapy: indications, contraindications, and agent selection | |
| EP0799043B1 (en) | Cyclophasic hormonal regimen containing antiprogestin and progestin | |
| KR0170764B1 (ko) | 피임제 패키지 | |
| Fleshner et al. | DHEA-S selectively impairs contextual-fear conditioning: support for the antiglucocorticoid hypothesis. | |
| US20050272712A1 (en) | Compositions and methods for treatment of premenstrual dysphoric disorder | |
| RO115115B1 (ro) | Terapie prin inlocuire hormonala | |
| AU2004257772A1 (en) | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration | |
| US20100075936A1 (en) | Use of glucocorticoid receptor antagonists for treatment of infectious conditions | |
| Kahn et al. | Oral contraceptives and mood | |
| GUSTAVSON et al. | Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens | |
| US8741880B2 (en) | Antiglucocorticoid therapy for the prevention of neurological damage in premature infants | |
| White et al. | Effects of long-term inhaled corticosteroids on adrenal function in patients with asthma | |
| Rible et al. | Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate | |
| KR20050038580A (ko) | 주요 우울 장애의 치료에 사용되는(11β,17β)-11-(1,3-벤조디옥솔-5-일)-17-히드록시-17-(1-프로피닐)-에스트라-4,9-디엔-3-온의 용도 | |
| EP1977752A1 (de) | Pharmazeutische Zubereitung zur Verminderung der Endometriose | |
| US6090799A (en) | Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1 | |
| CZ293771B6 (cs) | Použití steroidních antagonistů estrogenových receptorů pro výrobu léčiv | |
| Ramamoorthy et al. | Carbohydrate metabolic studies during twelve months of treatment with a low-dose combination oral contraceptive | |
| IL158744A (en) | Method for the treatment of insanity using glucocorticoid-specific receptor antagonists | |
| Li et al. | Effect of mifepristone and antiestrogens on uterine PGF2α and PGE2 concentrations in ovariectomized and pregnant rats | |
| Kaunitz | Three new formulations | |
| Loria et al. | 15 Steroids, Stress and the Neuroimmune Axis | |
| MXPA97007008A (es) | Uso de antiestrogenos para control natal en hombres |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |